Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
Cash to Debt No Debt
GNBT's Cash to Debt is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. GNBT: No Debt )
GNBT' s 10-Year Cash to Debt Range
Min: 0.09   Max: No Debt
Current: No Debt

F-Score: 3
Z-Score: -84.92
M-Score: -4.83
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history
ROA (%) -176.26
GNBT's ROA (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. GNBT: -176.26 )
GNBT' s 10-Year ROA (%) Range
Min: -204.35   Max: -48.62
Current: -176.26

-204.35
-48.62
ROC (Joel Greenblatt) (%) -7210.59
GNBT's ROC (Joel Greenblatt) (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. GNBT: -7210.59 )
GNBT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -7210.59   Max: -281.52
Current: -7210.59

-7210.59
-281.52
EBITDA Growth (%) -43.30
GNBT's EBITDA Growth (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. GNBT: -43.30 )
GNBT' s 10-Year EBITDA Growth (%) Range
Min: -68.3   Max: 108
Current: -43.3

-68.3
108
EPS Growth (%) -41.50
GNBT's EPS Growth (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. GNBT: -41.50 )
GNBT' s 10-Year EPS Growth (%) Range
Min: -54.6   Max: 46.3
Current: -41.5

-54.6
46.3
» GNBT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with GNBT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
EV-to-EBIT -2.46
GNBT's EV-to-EBIT is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. GNBT: -2.46 )
GNBT' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -2.46

Current Ratio 0.51
GNBT's Current Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. GNBT: 0.51 )
GNBT' s 10-Year Current Ratio Range
Min: 0.02   Max: 36.05
Current: 0.51

0.02
36.05
Quick Ratio 0.51
GNBT's Quick Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. GNBT: 0.51 )
GNBT' s 10-Year Quick Ratio Range
Min: 0.02   Max: 36.05
Current: 0.51

0.02
36.05

Valuation & Return

vs
industry
vs
history
Forward Rate of Return (Yacktman) -632.32
GNBT's Forward Rate of Return (Yacktman) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. GNBT: -632.32 )
GNBT' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0   Max: 0
Current: -632.32

Business Description

Industry: »
Compare: » details
Generex Biotechnology Corp. was incorporated in Delaware in September 1997. The Company is engaged in the research, development and commercialization of drug delivery systems and technologies. Its focus at the present time is its proprietary technology for the administration of formulations of large molecule drugs to the oral (buccal) cavity using a hand-held aerosol applicator. Through its wholly-owned subsidiary, Antigen, the Company has expanded its focus to include immunomedicines incorporating proprietary vaccine formulations. The Company's buccal delivery technology is a platform technology that has application to many large molecule drugs and provides a convenient, non-invasive, accurate and cost-effective way to administer such drugs. It has identified several large molecule drugs as possible candidates for development, including estrogen, heparin, monoclonal antibodies, human growth hormone and fertility hormone, but to date has focused its development efforts on one pharmaceutical product, Generex Oral-lyn, an insulin formulation administered as a fine spray into the oral cavity using its proprietary hand-held aerosol spray applicator known as RapidMist. The Company has received a Special Access Program (SAP) authorization from Health Canada for a patient-specific, physician-supervised treatment of Type-1 diabetes with Generex Oral-lyn in April 2008. In November 2008 the Company, together with its marketing partner Shreya Life Sciences Pvt. Ltd., officially launched Generex Oral-lyn in India under marketing name of Oral Recosulin. Using its buccal delivery technology, it also has launched a line of over-the-counter glucose and energy sprays , including Glucose RapidSpray(tm), Crave-NX(tm) 7-day Diet Aid Spray, and BaBOOM! Energy Spray. The Company's products would complement Generex Oral-lyn and might provide with an additional revenue stream prior to the commercialization of Generex Oral-lyn(tm) in other major jurisdictions. It received modest revenues from sales of its commercially available products, its confectionary, Glucose RapidSpray, a flavored glucose 'energy' spray supplemented with vitamins, BaBOOM! Energy Spray, and a fat-free glucose spray to aid in dieting, Crave-NX. All three products are available in retail stores and independent pharmacies in the United States and Canada. The Company's goal is to develop and commercialize its buccal delivery technology to administer large molecule drugs, including insulin, and proprietary vaccine formulations based upon two Antigen platform technologies to provide innovative biopharmaceutical products that offer the potential for efficacy and safety over existing products. The Company's faces competition from other providers of alternate forms of insulin. Some of its competitors include, Pfizer, Eli Lilly, and Novo Nordisk, have announced that they would discontinue development and/or sale of its inhalable forms of insulin.
» More Articles for OTCPK:GNBT

Headlines

Articles On GuruFocus.com
Weekly CFO Sells Highlight: TDG, GNBT, ADGE, HFC, AMSWA Jul 02 2012 
Weekly CFO Buys Highlight: FCTOA, GNBT, CTTC, ELGX, ARTC Nov 06 2010 
Weekly CFO Buys Highlight: GNBT, CTTC, COIN, AUMN, SOMH Oct 31 2010 
Weekly CFO Buys Highlight: Information Services Group Inc., BioFuel Energy Corp., Oculus Innovative Nov 22 2009 
Generex Biotechnology Corp. (GNBT) CEO Anna E Gluskin buys 10,000 Shares Nov 16 2009 
Generex Biotechnology Corp. (GNBT) CFO Rose C Perri buys 10,000 Shares Nov 16 2009 
Generex Biotechnology Corp. (GNBT) Files Quarterly Report for the Period Ended on 2008-10-31 Dec 15 2008 

More From Other Websites
GENEREX BIOTECHNOLOGY CORP Financials Jun 17 2014
Generex Announces Interview of Dr. Eric von Hofe, President of Antigen Express, Following Recent... Jun 17 2014
Generex/Antigen Express Announce Interview of MD Anderson's Dr. Elizabeth Mittendorf, Principal... Jun 12 2014
Generex / Antigen Express to Participate in 2014 BIO International Convention Jun 10 2014
GENEREX BIOTECHNOLOGY CORP Files SEC form 10-Q, Quarterly Report Jun 06 2014
GENEREX BIOTECHNOLOGY CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 23 2014
Generex Announces Presentation of Primary Efficacy Data & Immunological Response from the Phase II... May 20 2014
Generex Announces Antigen Express AE37 Breast Cancer Vaccine Abstract Presentations at ASCO 2014... Apr 23 2014
GENEREX BIOTECHNOLOGY CORP Files SEC form 8-K, Unregistered Sale of Equity Securities, Amendments to... Mar 28 2014
Generex Announces $2,075,000 Capital Investment Mar 27 2014
Generex Announces $2,075,000 Capital Investment Mar 27 2014
Generex/Antigen Express Announces Participation on Panel at Upcoming Cancer Immunotherapeutics... Mar 26 2014
Generex/Antigen Express Announces Participation on Panel at Upcoming Cancer Immunotherapeutics... Mar 26 2014
GENEREX BIOTECHNOLOGY CORP Files SEC form 10-Q, Quarterly Report Mar 07 2014
Generex Subsidiary Antigen Express Receives Patents for Vaccines Targeting HPV Induced Cancers and... Mar 05 2014
Generex Subsidiary Antigen Express Receives Patents for Vaccines Targeting HPV Induced Cancers and... Mar 05 2014
Generex Announces Publication of Biomarker Studies Related to the Antigen Express Novel... Feb 27 2014
Generex Announces Publication of Biomarker Studies Related to the Antigen Express Novel... Feb 27 2014
Generex Provides Update on Antigen Express Phase II AE37 Breast Cancer Vaccine Trial Feb 12 2014
Generex/Antigen Express Interview on Clear Channel Business Talk Radio DFW 1190AM by Host Michael... Feb 12 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide